Phoenix Bio

論文一覧

論文一覧

論文一覧

Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

    Yano, J. Kawamoto, K. Shimotsuma, Y. Ogata, K. Matsunaga, K. Abe, J. Fukunaga, S. Osimitz, T. G. Lake, B. G. Asano, H.
    Regul Toxicol Pharmacol. 2025 Dec;163:105929. doi: 10.1016/j.yrtph.2025.105929.

    RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

      Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
      Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

      A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

        Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
        Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

        Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

          Takamatsu, S. Morita, C. Sakon, D. Nakamura, K. Hishii, H. Kondo, J. Ueda, K. Miyoshi, E.
          Viruses. 2025 Sep 15;17(9):1242. doi: 10.3390/v17091242.

          Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment

            Yamazaki, K. Kubara, K. Sugahara, G. Muto, H. Yamamoto, M. Mano, Y. Mitsuhashi, K. Yamasaki, C. Ishida, Y. Tateno, C. Suzuki, Y.
            Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466.

            Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

              Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
              Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

              Modeling of hepatitis B virus infection spread in primary human hepatocytes

                Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
                J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

                Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

                  Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
                  Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

                  miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

                    Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
                    Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

                    Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

                      Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
                      JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

                      An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

                        Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
                        Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

                        Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

                          Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
                          Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

                          Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

                            Tanaka, Yasuhito
                            Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

                            Application of humanized mice to toxicology studies: properties of chimeric mice with humanized liver (PXB-mice) for hepatotoxicity

                              Sultana, N. Izawa, T. Kamei, T. Fujiwara, S. Ito, Y. Takami, Y. Kuwamura, M.
                              Drug Metab Dispos. 2025 Feb;53(2):100025. doi: 10.1016/j.dmd.2024.100025.

                              Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

                                Nishitsuji, H. Naito, Y. Murakami, Y. Sugiyama, M. Mizokami, M. Shoji, I. Murata, T. Shimotohno, K.
                                Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.

                                Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

                                  Nosaka, T. Naito, T. Akazawa, Y. Takahashi, K. Matsuda, H. Ohtani, M. Nishizawa, T. Okamoto, H. Nakamoto, Y.
                                  PLoS One. 2025 Mar 6;20(3):e0314581. doi: 10.1371/journal.pone.0314581.

                                  Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

                                    Miyake, T. Fujita, Y. Hirabayashi, M. Komiyama, N. Morita, K. Tachibana, T. Terao, K.
                                    Drug Metab Dispos. 2025 Feb 10;53(4):100050. doi: 10.1016/j.dmd.2025.100050.

                                    Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease

                                      Morioka, S. Sanoh, S. Ishida, Y. Furukawa, S. Ogawa, Y.Kotake, Y. Tateno, C.
                                      Arch Toxicol. 2025 Feb 21. doi: 10.1007/s00204-025-03986-5.

                                      Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

                                        Karlsson, I. B. Ekdahl, A. Etchingham-Coll, H. Li, X. Q. Ericsson, C. Ahlqvist, M. Samuelsson, K.
                                        Int J Mol Sci. 2025 Jan 28;26(3):1141. doi: 10.3390/ijms26031141

                                        Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

                                          Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
                                          FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.